Andrew Swanson, DO
Family Medicine · Sparks, NVNPI 1740267020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AstraZeneca at 28.7% of the total. Reporting peaked in 2019 at $1,440 and has fallen 88.2% since, to $170 in 2025. Among family medicine clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$732
- GSK$680
- Pfizer$549
- Boehringer Ingelheim$290
- Novo Nordisk$268
- plus $967 from 13 others
What the payments were for
- Food & beverage$4,77198%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $1,404 |
| Lilly USA, LLC | 22 | $732 |
| GSK | 29 | $680 |
| Pfizer | 24 | $549 |
| Boehringer Ingelheim | 19 | $290 |
| Novo Nordisk | 10 | $268 |
| Edwards Lifesciences | 3 | $224 |
| AbbVie(2 entities) | 6 | $184 |
| Astellas Pharma US Inc | 5 | $180 |
| Bayer | 3 | $120 |
| Merck | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Eisai Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $21 |
| Abbott | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$454
- COLOGUARD$129
- BREZTRI$120
- JARDIANCE$117
- EMGALITY$111
- BEXSERO$107
- Edwards SAPIEN 3 Transcatheter Heart Valve$103
- TRELEGY ELLIPTA$102
- SAPIEN 3 Ultra RESILIA$100
How this compares
$4,889 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $77,685 |
| FarxigaDapagliflozin Propanediol | 65 | $56,353 |
| OzempicSemaglutide | 26 | $42,063 |
| EliquisApixaban | 39 | $34,741 |
| JardianceEmpagliflozin | 25 | $28,171 |
| MounjaroTirzepatide | 14 | $23,904 |
| XareltoRivaroxaban | 14 | $8,580 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,000 |
| Atorvastatin Calcium | 270 | $4,120 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $3,847 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 55 | $3,555 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 105 | $3,140 |
| Valsartan | 86 | $3,070 |
| Tamsulosin Hcl | 86 | $2,739 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $680 | $83,685103 claims |
| AstraZenecaFarxiga | $1,404 | $56,35365 claims |
| Novo NordiskOzempic | $268 | $42,06326 claims |
| PfizerEliquis | $549 | $34,74139 claims |
| Boehringer IngelheimJardiance | $290 | $28,17125 claims |
| Lilly USA, LLCMounjaro | $732 | $23,90414 claims |
| AbbVieSynthroid | $184 | $1,61020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.
Other family medicine in Sparks
- Ronald HicksSparks$9K
- Sangeeta WagnerSparks$8K
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Bayo Curry-WinchellReno$74K
- Warren MagnusLas Vegas$70K
- Catherine McCarthyReno$68K
- Kimberly AdamsLas Vegas$51K
- Badi EghterafiHenderson$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.